Zydus Cadila, India’s fourth largest pharmaceutical group and a global 
healthcare provider announced that it has acquired 100% stake in a Spain’s Laboratorios Combix to gain entry into the Spainsh market.
Laboratorios Combix, which has a pure generic focus, provides the right fit for Zydus’ entry strategy into a market that is estimated at USD 1.7 billion and is growing at 21.5%, as against 6% for the overall pharmaceutical market in 2007.
Established in 2006, Combix with a sales and marketing focus has a solid portfolio covering 17 molecules.
establishing an SEZ 
